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AbsTrACT
Objectives international spread has contributed 
substantially to the high prevalence of antimicrobial 
resistant (aMr) Neisseria gonorrhoeae infections 
worldwide. We compared the prevalence of aMr 
gonococcal isolates among native persons to foreign- 
born (reporting country different from country of birth) 
persons, and describe the epidemiological and clinical 
characteristics of foreign- born patients and their 
associations to aMr.
Methods We analysed isolates and patient data reported 
to the european gonococcal antimicrobial surveillance 
Programme (euro- gasP) 2010–2014 (n=9529).
results Forty- three per cent of isolates had known 
country of birth and 17.2% of these were from persons 
born abroad. almost 50% of foreign- born were from the 
WhO european region (13.1% from non- european Union 
[eU] and the european economic area [eea] countries). 
compared with isolates from natives, isolates from 
foreign- born had a similar level (p>0.05) of azithromycin 
resistance (7.5% vs 7.2%), ciprofloxacin resistance (50.0% 
vs 46.3%) and of decreased susceptibility to ceftriaxone 
(1.9% vs 2.8%); a lower rate of cefixime resistance (5.7% 
vs 3.6%, p=0.02), and a higher proportion of isolates 
producing penicillinase (8.4% vs 11.7%, p=0.02). among 
isolates from persons born outside eU/eea, the level of 
decreased susceptibility to ceftriaxone was higher (1.8% vs 
3.5%, p=0.02), particularly in those from the WhO eastern 
Mediterranean region and non- eU/eea WhO european 
countries (1.9% vs 9.6% and 8.7%, respectively, p<0.01). 
in multivariable analysis, foreign- born patients with aMr 
isolates were more likely to be from non- eU/eea WhO 
european countries (adjusted Or [aOr]: 3.2, 95% ci 1.8 
to 5.8), WhO eastern Mediterranean countries (aOr: 1.8, 
95% ci 1.1 to 3.3) and heterosexual males (aOr: 1.8, 
95% ci 1.2 to 2.7).
Conclusions importation of aMr strains remains an 
important threat in the eU/eea. research to improve 
understanding of sexual networks within foreign born 
and sexual tourism populations could help to inform 
effective tailor- made interventions. The euro- gasP 
demonstrates the public health value of quality- assured 
surveillance of gonococcal aMr and the need for 
strengthened aMr surveillance, particularly in the non- 
eU/eea WhO european region.
InTrOduCTIOn
Neisseria gonorrhoeae (gonococcus) has shown 
an extraordinary ability to develop antimicrobial 
resistance (AMR) to any antimicrobial introduced 
for gonorrhoea treatment. In the WHO European 
Region, a high prevalence of resistance to ciproflox-
acin, penicillins and tetracycline has been observed 
for many years. In the last decade, in vitro and clin-
ical resistance, resulting in treatment failures, to the 
extended- spectrum cephalosporins (ESCs) cefixime 
and ceftriaxone, as well as azithromycin have also 
emerged.1–8
To mitigate the emergence and/or dissemination 
of AMR gonococcal strains, ceftriaxone (500 mg 
single dose intramuscularly) plus azithromycin (2 
g single oral dose) is currently recommended for 
empirical first- line dual therapy of uncomplicated 
gonorrhoea in Europe. Similar dual therapy regi-
mens (ceftriaxone 250–500 mg plus azithromycin 1 
g) are recommended in the USA, Canada, Australia, 
Brazil and globally by WHO, that is, when local, 
comprehensive, regular and quality- assured AMR 
surveillance is not supporting monotherapy. 
However, in some countries ceftriaxone high- dose 
monotherapy remains recommended, for example, 
Japan (1 g) and China (0.5–1 g).1 8 9 The emergence 
of ceftriaxone resistance and relatively high rates 
of azithromycin resistance reported in Europe and 
globally1–3 5–10 threaten the effectiveness of these 
regimens, which are currently the last evidence- 
based options for first- line empirical treatment. The 
first global failure to treat gonorrhoea with dual 
antimicrobial therapy was reported in 2016.11 In 
early 2018, the first gonococcal strain with ceftri-
axone resistance combined with high- level resist-
ance to azithromycin was reported from England12 
followed by two similar cases in Australia.13 Due 
to the development of difficult- to- treat or possibly 
untreatable gonorrhoea, AMR N. gonorrhoeae has 
been designated as a priority global health issue by 
WHO.9
Robust gonococcal AMR surveillance is essen-
tial to monitor the emergence and spread of AMR 
gonococcal strains,2 3 6–8 which has been strongly 
emphasised by the Global Action Plan14 and the 
European Response Plan,3 developed by WHO 
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and the European Centre for Disease Prevention and Control 
(ECDC), respectively. Since 2009, ECDC has coordinated the 
European Gonococcal Antimicrobial Surveillance Programme 
(Euro- GASP), which is a sentinel surveillance system that moni-
tors antimicrobial susceptibility of gonococcal isolates across 
Member States of the European Union (EU) and the European 
Economic Area (EEA). Linking the laboratory data to epidemi-
ological data of the corresponding patients, Euro- GASP allows 
surveillance to be focused in subpopulations and analysis of 
patient risk groups.3 6
In Europe, international migration has been significant during 
recent decades.15 16 Particular groups of migrants, especially 
those of lower socioeconomic status, refugees and sex workers, 
can be more at risk and suffer disproportionally from STIs,17 
including gonorrhoea.18 19 Migrants and other mobile popula-
tions can play a significant role in the international transmission 
of AMR including AMR gonococcal strains, and are considered 
key populations for gonorrhoea control by WHO.2 3 14 20 Histori-
cally, most gonococcal AMR is considered to have initially devel-
oped in the WHO Western Pacific Region (WPR), particularly 
in Japan, and subsequently spread globally.2 8 The reasons for 
the initial emergence of gonococcal AMR in WPR are multifac-
eted and include the high rates of gonorrhoea, the lack of effec-
tive disease- control measures, the extensive use and misuse of 
antimicrobials and the lack of optimal monitoring of AMR and 
treatment failures.2 8 9 14
The objectives of this study were to investigate the preva-
lence of AMR gonococcal isolates among foreign- born cases of 
gonorrhoea reported through Euro- GASP from 2010 to 2014, 
compare isolates from such cases with gonococcal isolates from 
native born cases, and describe the epidemiological and clin-
ical characteristics of foreign- born patients with AMR gono-
coccal isolates (resistance to at least one antimicrobial), with the 
purpose of improving the understanding of the distribution of 
AMR gonococcal strains among patient populations in the EU/
EEA and inform targeted interventions.
MATErIAls And METhOds
data source
We analysed Euro- GASP isolates and corresponding patient data 
from 2010 to 2014. Euro- GASP has been described in detail else-
where.3 6 21 Briefly, participating sites in each Euro- GASP country 
collected around 100 gonococcal isolates (200 isolates in the 
UK, Spain and the Netherlands, which report higher numbers 
of gonorrhoea cases) from consecutive gonorrhoea patients 
(one isolate per patient and infection episode). The collection 
periods were April–May and October–November during 2010–
2013, and September–November in 2014. We defined persons 
as foreign- born when the reporting country differed from the 
country of birth20 and native as those with reporting country 
identical to country of birth.22 Geographic region of origin was 
assigned based on WHO definitions.7
Antimicrobial susceptibility testing
AMR testing was conducted using Etest for ceftriaxone and 
cefixime, agar dilution breakpoint method or Etest for azith-
romycin and ciprofloxacin and nitrocefin test for detection of 
penicillinase production.3 6 21 The WHO gonococcal reference 
strains WHO G, K, M, O and P23 should be used for quality 
control and all laboratories performing AMR testing are 
required to participate with acceptable results in the Euro- GASP 
external quality assessment. The minimum inhibitory concen-
trations (MICs; mg/L) of each antimicrobial were interpreted 
into resistance, intermediate susceptibility or susceptibility using 
breakpoints stated by the European Committee on Antimicrobial 
Susceptibility Testing.24 Strains with a ceftriaxone MIC of 0.12 
mg/L have previously caused gonorrhoea treatment failures and 
can be considered to have a decreased susceptibility.8 25 26 Only 
whole MIC doubling dilutions were analysed.
Epidemiological and clinical variables and statistical analysis
Epidemiological and clinical data analysed included: year of 
diagnosis, age (<25, 25–44, ≥45 years), area of origin (Euro-
pean Region [EUR; 28 EU countries, 3 EEA countries and 23 
non- EU/EEA countries]; Eastern Mediterranean Region [EMR]; 
Region of the Americas [AMRO]; African Region [AFR]; 
South- East Asia Region [SEAR] and WPR), sexual orientation 
(heterosexual females, heterosexual males and men who have 
sex with men [MSM]), site of infection (anorectal, urogenital 
and pharyngeal), HIV status (positive, negative), previously diag-
nosed with gonorrhoea (yes, no) and probable country of infec-
tion (reporting country, others). AMR isolates from foreign- born 
patients were compared with those from native patients; and 
AMR isolates from patients born in EU/EEA were compared 
with AMR isolates from patients born outside EU/EEA. In our 
analysis, we excluded countries that had not reported consis-
tently throughout the study period (Estonia, Iceland, Poland and 
Romania). Statistical significance was determined by Pearson’s 
χ2 test or by Fisher’s exact test if cell numbers were <5, with 
two- sided p values of <0.05 considered as significant. Data from 
2010 to 2014 were combined. Among foreign- born patients, the 
association of gonococcal infection resistant to at least one anti-
microbial with epidemiological and clinical characteristics were 
investigated using univariate and multivariable logistic regres-
sion analyses. Results were expressed with crude ORs (cORs) 
and adjusted ORs (aORs) and their 95% CI. Those variables 
that were associated with the outcome in univariate models 
at p<0.10 were included in the multivariable model. Using a 
backward stepwise approach, those that remained significant 
(p<0.05) were retained in the final model. Statistical analysis 
was performed in SPSS V.20.
Ethical considerations
All examined gonococcal isolates were cultured and stored as 
part of routine diagnostics (standard care). Patient data were 
reported as part of a surveillance programme (EU Decisions 
2119/98/EC and 1082/2013/EU) with no patient- identifiable 




Out of the 9529 isolates, the patient’s country of birth was 
known for 4098 (43%) isolates and was reported by 14 (60.8%) 
of the Euro- GASP countries (online supplementary table 1). Of 
these isolates (n=4098), 704 (17.2%) were from foreign- born 
patients. The Netherlands (34.9%), Ireland (13.1%) and the 
UK (12.9%) reported 60.9% of the isolates from foreign- born 
patients (online supplementary table 1). Among the foreign- 
born patients, 345 (49%) were from another country in WHO 
EUR (253 [35.9%] from EU/EEA and 92 [13.1%] from non- EU/
EEA countries), 174 (24.7%) from WHO AMRO, 83 (11.8%) 
from WHO EMR, 55 (7.8%) from WHO AFR, 25 (3.6%) from 
WHO WPR and 22 (3.1%) from WHO SEAR. The proportion 
of isolates reported from foreign- born persons did not vary 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































significantly during the study period (ranging from 13.1% to 
18.5%; p=0.19).
Antimicrobial resistance and decreased susceptibility to 
ceftriaxone from persons born outside the reporting country
The proportion of isolates with AMR to at least one antimi-
crobial was similar for foreign- born persons compared with 
isolates from native persons (natives: 53.5%; foreign born: 
52.0%, p=0.45). Compared with isolates from native persons, 
isolates from foreign- born had lower level of cefixime resistance 
(5.7% vs 3.6%, p=0.02), and similar rates of azithromycin resis-
tance (7.5% vs 7.2%, p=0.8), ciprofloxacin resistance (50.0% 
vs 46.3%, p=0.07) and decreased susceptibility to ceftriaxone 
(1.9 vs 2.8, p=0.10). Only the proportion of isolates producing 
penicillinase was higher among foreign- born persons (8.4% vs 
11.7%, p=0.02). All isolates from foreign- born persons were 
also susceptible to ceftriaxone; however, four (0.1%) isolates 
from natives (two MSM and two heterosexual males) were resis-
tant to ceftriaxone, all with a ceftriaxone MIC of 0.25 mg/L 
(table 1).
The proportion of isolates with AMR to at least one antimi-
crobial was significantly higher among those born in non- EU/
EEA WHO EUR countries and in WHO EMR countries than 
in native patients (53.5% vs 78.3% and 68.7%, respectively, 
p<0.01). Those born in non- EU/EEA WHO EUR countries had 
the highest rates of resistance to ciprofloxacin (71.7%), azithro-
mycin (11.2%) and cefixime (9.1%), and the second highest rate 
of decreased susceptibility to ceftriaxone (8.7%). Isolates from 
patients born in WHO EMR had the highest level of decreased 
susceptibility to ceftriaxone (9.6%), and additionally the second 
highest rate of resistance to ciprofloxacin (66.3%) and cefixime 
(8.9%). The rates of decreased susceptibility to ceftriaxone in 
those coming from WHO EMR countries and non- EU/EEA 
WHO EUR were significantly higher than in native patients 
(1.9% vs 9.6% and 8.7%, respectively, p<0.01) (table 1). Data 
including isolates with unknown country of birth are summa-
rised in online supplementary table 2.
Antimicrobial resistance in isolates from persons born outside 
the Eu/EEA
Isolates from patients born outside the EU/EEA when compared 
with patients born in the EU/EEA had similar levels of resis-
tance to ciprofloxacin (n=1796, 49.4% vs n=223, 49.4%; 
p=1.0), azithromycin (n=268, 7.4% vs n=33, 7.5%; p=1.0), 
cefixime (n=198, 5.5% vs n=19, 4.3%; p=0.3) and penicilli-
nase production (n=261, 8.6% vs n=36, 11.8%; p=0.07). All 
four ceftriaxone- resistant isolates were from patients born in the 
EU/EEA; however, the proportion of decreased susceptibility 
to ceftriaxone was higher among isolates from patients born 
outside the EU/EEA (n=67, 1.8% vs n=16, 3.5%; p=0.02).
Epidemiological and clinical characteristics of antimicrobial 
resistant isolates from foreign-born patients compared with 
isolates from native patients
Foreign- born patients with AMR isolates had a mean age of 
31.1 years (SD 9.1) and natives of 33.0 years (11.3). Compared 
with isolates from native persons, foreign- born persons were 
younger (82.9% vs 89.6% were <45 years, p<0.01), had higher 
proportions of anorectal (11.0% vs 18.4%, p<0.01) and lower 
frequency of urogenital (83.9% vs 74.7%, p<0.01) infections, 
as well as higher proportion of infections acquired abroad 
compared with the reporting country (5.7% vs 11.0%, p<0.01) 
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Table 2 Epidemiological and clinical characteristics of patients with 
antimicrobial resistant isolates by country of birth (n=2183), Euro- 
GASP 2010–2014
Epidemiological and clinical 
characteristics
Country of birth








2010 225 (12.4) 31 (8.5) 0.02 0.04
2011 383 (21.1) 66 (18.0) 0.2
2012 393 (21.6) 99 (27.0) 0.02
2013 443 (24.4) 84 (23.0) 0.59
2014 373 (20.5) 86 (23.5) 0.2
Age (years)
(n=2165)
<25 459 (25.5) 96 (26.3) <0.01 0.79
25–44 1033 (57.4) 231 (63.3) 0.04






169 (12.1) 29 (8.5) 0.14 –
Heterosexual 
males
637 (45.7) 158 (46.2) –
Men who have 
sex with men
589 (42.2) 155 (45.3) –
Isolation site
(n=2127)
Anorectal 195 (11.0) 66 (18.4) <0.01 <0.01
Urogenital 1484 (83.9) 268 (74.7) <0.01
Pharyngeal 89 (5.0) 25 (7.0) 0.15
HIV status
(n=1396)
Positive 144 (12.7) 42 (15.8) 0.19 –




Yes 181 (14.7) 31 (12.8) 0.48 –






1081 (94.3) 162 (89.0) <0.01 –
Other country 65 (5.7) 20 (11.0) –
*Calculated only for those variables with more than two categories and p value 
<0.05.
Euro- GASP, European Gonococcal Antimicrobial Surveillance Programme.
(table 2). Data including isolates with unknown country of birth 
are summarised in online supplementary table 3.
risk factors for antimicrobial resistant isolates among 
foreign-born patients
Among foreign- born persons, those with N. gonorrhoeae isolates 
resistant to at least one antimicrobial were found to be more 
likely from non- EU/EEA WHO EUR countries (cOR: 4.1, 95% 
CI 2.3 to 7.1) and from WHO EMR (cOR: 2.5, 95% CI 1.4 to 
4.2), heterosexual males (cOR: 2.3, 95% CI 1.6 to 3.2), HIV 
negative (cOR: 1.7, 95% CI 1.1 to 2.7), without a previous 
gonorrhoea episode (cOR: 1.7, 95% CI 1.0 to 2.9) and with 
urogenital site of infection (cOR: 1.9, 95% CI 1.3 to 2.8). In the 
multivariable analysis, the associations remained significant for 
being from non- EU/EEA WHO EUR country (aOR: 3.2, 95% 
CI 1.8 to 5.8), from EMR (aOR: 1.8, 95% CI 1.1 to 3.3) and 
heterosexual male (aOR: 1.8, 95% CI 1.2 to 2.7) (table 3). There 
was no association with age and year of diagnosis.
dIsCussIOn
In our study, the proportion of overall AMR isolates among 
native and foreign- born patients (53.5%, n=1817, vs 52.0%, 
n=366; p=0.45) was similar. However, gonococcal AMR levels 
for cefixime (more common among native patients) and penicil-
linase production (more common among foreign- born patients) 
differed significantly depending on the region of birth of patients. 
Over the last decade, international transmission of AMR gono-
coccal strains has been recorded in detail, for example, the 
multidrug- resistant NG- MAST genogroup 1407 clone associ-
ated with cefixime and ciprofloxacin resistance, increased MICs 
of ceftriaxone and azithromycin and causing the majority of 
verified cephalosporin treatment failures has been spreading in 
Europe, the USA and Canada.2 8 27–29 Furthermore, resistance or 
decreased susceptibility to ceftriaxone and/or resistance to azith-
romycin has been described in many regions globally.7 Recently, 
the first three cases of ceftriaxone resistance combined with high- 
level resistance to azithromycin12 13 have been identified, two of 
them in men who had travelled to southeast Asia and had sexual 
intercourse with locally resident women. During recent years, 
in the EU/EEA, the level of cefixime resistance has decreased 
and appeared to stabilise at around 2%, ceftriaxone resistance 
has been exceedingly rare and azithromycin resistance has been 
stably relatively high (approximately 7%–8%).6
The role of importation of AMR strains in the transmission 
and prevalence of AMR in a country or region is difficult to 
elucidate and is largely unexplored. Global population mobility 
and international travel including sex tourism are providing 
additional challenges in the prevention and control of N. gonor-
rhoeae AMR internationally.30 Recent data from Euro- GASP also 
showed that the majority (94%) of AMR gonococcal isolates are 
most likely acquired in the reporting country.21 In the present 
study, the higher rate of decreased susceptibility to ceftriaxone in 
isolates from persons born outside the EU/EEA (1.8% vs 3.5%, 
p=0.02) and particularly in those from WHO EMR countries and 
non- EU/EEA WHO EUR (1.9% vs 9.6% and 8.7%, respectively, 
p<0.01), and the higher proportion of foreign- born patients 
likely infected abroad versus in the reporting country (5.7% vs 
11.0%, p<0.01) indicate that importation of AMR gonococcal 
strains, and especially with decreased susceptibility to ceftri-
axone, to the EU/EEA by foreign- born persons remains a threat. 
Despite this, native cases, although more likely to acquire gonor-
rhoea in the reporting country, are larger in number and there-
fore may represent a greater risk for importation of gonorrhoea. 
Further detailed molecular investigations of the international 
transmission of gonococcal strains with decreased susceptibility 
or resistance to ESCs and azithromycin are essential.27
Although absolute numbers were small, isolates from foreign- 
born persons from non- EU/EEA WHO EUR countries had the 
highest rates of resistance to ciprofloxacin (71.7%), azithromycin 
(11.2%) and cefixime (9.1%), and together with those from 
WHO EMR, of decreased susceptibility to ceftriaxone (8.7% 
and 9.6%, respectively). The major challenge in the non- EU/EEA 
part of the WHO EUR Region (former Soviet Union countries 
in Eastern Europe and Central Asia) is the very limited quality- 
assured surveillance of gonococcal AMR.4 5 7 [w1,w2] In this 
region, the burden of gonorrhoea is estimated to be relatively 
high, and, together with suboptimal laboratory diagnostics, lack 
of gonococcal culture, scarce surveillance of both gonorrhoea 
cases and gonococcal AMR and misuse of antimicrobials of 
uncertain quality and origin without prescription from a physi-
cian predispose for emergence and rapid spread of gonococcal 
AMR.7 [w1–w3] The rapid spread of AMR might be further 
accelerated by the introduction AMR gonococcal strains in more 
antimicrobial susceptible populations. For example, it has been 
shown that some ciprofloxacin resistance mutations enhance the 
fitness of the gonococcal strains,[w4] which can result in an out- 
competition of the ciprofloxacin- susceptible strains due to both 
the ciprofloxacin resistance and the enhanced fitness. Despite 
that quality- assured data are available from Russia and Belarus,4 5 
a quality- assured GASP in the Eastern and Central Asian part of 
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Table 3 Univariate and multivariate analysis of foreign- born patients with antimicrobial resistant isolates (n=366), Euro- GASP 2010–2014
Epidemiological and clinical characteristics
resistant isolates from foreign- born patients
no. (%)
Crude Or Adjusted Or




2010 31/50 (62.0) 1
2011 66/143 (46.2) 0.5 (0.2 to 1.0) 0.05
2012 99/183 (54.1) 0.7 (0.3 to 1.3) 0.32
2013 84/173 (48.6) 0.5 (0.3 to 1.1) 0.09




<25 96/177 (54.2) 0.7 (0.4 to 1.4) 0.4
25–44 231/461 (50.1) 0.6 (0.3 to 1.1) 0.13




EU/EEA 118/253 (46.6) 1 1
Non- EU/EEA WHO EUR 72/92 (78.3) 4.1 (2.3 to 7.1) <0.01 3.2 (1.8 to 5.8) <0.01
WHO EMR 57/83 (68.7) 2.5 (1.4 to 4.2) <0.01 1.8 (1.1 to 3.3) 0.02
WHO AMRO 68/174 (39.1) 0.7 (0.4 to 1.0) 0.12 0.7 (0.5 to 1.1) 0.21
WHO AFR 22/55 (40.0) 0.7 (0.4 to 1.3) 0.37 0.6 (0.3 to 1.2) 0.17
WHO SEAR 14/22 (63.6) 2.0 (0.8 to 4.9) 0.13 1.9 (0.7 to 5.0) 0.13




Heterosexual females 29/67 (43.3) 1.0 (0.6 to 1.7) 0.94 1.0 (0.6 to 1.8) 0.81
Heterosexual males 158/248 (63.7) 2.3 (1.6 to 3.2) <0.01 1.8 (1.2 to 2.7) <0.01




Ano- rectal 66/164 (40.2) 1
Urogenital 268/469 (57.1) 1.9 (1.3 to 2.8) <0.01
Pharyngeal 25/61 (41.0) 1.0 (0.5 to 1.8) 0.92
HIV status
(n=555)
Positive 42/115 (36.5) 1 <0.01 – –
Negative 223/440 (50.7) 1.7 (1.1 to 2.7)
Previous gonorrhoea
(n=425)
Yes 31/68 (45.6) 1 0.03 – –
No 212/357 (59.4) 1.7 (1.0 to 2.9)
Probable country of 
infection
(n=319)
Reporting country 162/286 (56.6) 1 0.66 – –
Other country 20/33 (60.6) 1.1 (0.5 to 2.4)
EEA, European Economic Area; EU, European Union; Euro- GASP, European Gonococcal Antimicrobial Surveillance Programme; WHO AFR, WHO African Region; WHO AMRO, WHO 
Region of the Americas; WHO EMR, WHO Eastern Mediterranean Region; WHO SEAR, WHO South- East Asia Region; WHO WPR, WHO Western Pacific Region.
WHO EUR is still needed. As previously stressed,7 such a GASP 
is crucial to also develop in the WHO EMR.
In the multivariable analysis, among foreign- born persons, 
those from non- EU/EEA WHO EUR (aOR: 3.2, 95% CI 1.8 
to 5.8), from WHO EMR (aOR: 1.8, 95% CI 1.1 to 3.3) and 
heterosexual males (aOR: 1.8, 95% CI 1.2 to 2.7) were associ-
ated with AMR gonococcal isolates. Most likely, area of origin, 
country of infection, sexual orientation and additional epidemio-
logical characteristics can play a major role in the spread of AMR 
gonococcal strains in many countries. These results are in line 
with recent data from Euro- GASP, where geometric means were 
higher for both cefixime and ceftriaxone MICs for heterosexual 
males compared with MSM (p<0.001) and females (cefixime: 
p=0.014, ceftriaxone: p=0.025).[w5] In England and Wales, a 
higher rate of decreased susceptibility to ceftriaxone has been 
reported within MSM compared with heterosexual males.[w6] 
Among heterosexual males, those with older age (especially ≥35 
years), rapid partner turnover and sex abroad also had a higher 
proportion of decreased susceptibility to ceftriaxone.[w6] The 
emergence and spread of gonococcal AMR is such a dynamic 
phenomenon that transmission of AMR gonococcal strains may 
spread from heterosexual to MSM networks or vice versa very 
quickly. Further studies on the molecular epidemiology of AMR 
gonococcal strains27 can contribute to a better understanding 
of epidemiology and population dynamics in the national and 
international spread of AMR gonococcal strains.
The present study includes other limitations such as the 
absence of participation of some countries along with differ-
ences in representativeness that limit the generalisability of the 
findings. In addition, the limited number of isolates resistant to 
ceftriaxone, cefixime and azithromycin did not allow for analysis 
by antimicrobial. When considering the AMR all together, the 
high levels of resistance to ciprofloxacin account for most of the 
AMR described. Missing patient data, particularly for country of 
birth (57%), and the different proportions of reported patient 
characteristics between different countries may bias the results. 
The results might also not be representative of all foreign- 
born cases of gonorrhoea as some categories of foreign- born 
persons such as refugees, undocumented migrants, trafficked 
people, migrant MSM and subgroups of migrant women can 
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face particular challenges in accessing healthcare services. Male 
heterosexuals are over- represented in Euro- GASP, likely because 
the majority of males with urogenital gonorrhoea are sympto-
matic and attend for testing, the high sensitivity of culture for 
these males, and possibly due to undeclared or misclassified 
MSM. In some Euro- GASP countries, under- reporting of patient 
data is also due to ethical or juridical restrictions around linking 
patient and isolate data. The under- representation of patients 
younger than 25 years in Euro- GASP may be due to Chlamydia 
trachomatis screening programmes targeting this group and their 
use of dual C. trachomatis and N. gonorrhoeae molecular tests 
instead of culture for diagnosis.
Increasing the number of participating countries and exam-
ined isolates, facilitating and promoting culture of N. gonor-
rhoeae, achieving more complete reporting of epidemiological 
data, particularly data on country of birth, country of infection 
and sexual orientation and increasing the representativeness are 
high priorities for Euro- GASP.6
COnClusIOns
Importation of AMR gonococcal strains into the EU/EEA from 
other geographic regions worldwide poses a threat for emer-
gence and subsequent rapid spread of gonococcal AMR in 
Europe. Effective disease- control measures targeted towards 
foreign- born originating from countries with higher levels 
of gonococcal AMR and those returning to their country of 
birth to visit friends and relatives could be valuable. These 
results from Euro- GASP demonstrate the public health value 
of quality- assured surveillance of gonococcal AMR, which is 
required throughout the WHO European Region. Improving 
the completeness of demographic and risk factor data in 
Euro- GASP would provide strengthened information for 
public health action. It is also essential to further strengthen 
and expand the WHO Global GASP,7 particularly in regions 
with very limited AMR data such as WHO EMR and WHO 
AFR, but also in regions with high rates of AMR such as SEAR 
and especially WPR. Further research to improve the under-
standing of sexual networks within foreign- born and sexual 
tourism populations will help to inform effective tailor- made 
interventions.
Additional references can be found in the online supplemen-
tary file.
Key messages
 ► Importation of antimicrobial resistant (AMR) gonococcal 
strains and particularly those with decreased susceptibility 
to ceftriaxone, into the European Union/European Economic 
Area from other geographic regions worldwide is of 
importance.
 ► Area of geographic origin and sexual orientation of patients 
are both important risk factors for AMR in gonococcal strains.
 ► Robust surveillance of Neisseria gonorrhoeae antimicrobial 
susceptibility globally is essential to identify emerging AMR, 
monitor AMR trends and inform treatment guidelines.
 ► Implementation of more effective disease- control measures, 
including these related to foreign- born populations that 
originate from countries with increased AMR, is needed.
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